Clinical Hemorheology and Microcirculation - Volume 11, issue 6
Purchase individual online access for 1 year to this journal.
Price: EUR 185.00
Impact Factor 2021: 2.375
Clinical Hemorheology and Microcirculation, a peer-reviewed international scientific journal, serves as an aid to understanding the flow properties of blood and the relationship to normal and abnormal physiology. The rapidly expanding science of hemorheology concerns blood, its components and the blood vessels with which blood interacts. It includes perihemorheology, i.e., the rheology of fluid and structures in the perivascular and interstitial spaces as well as the lymphatic system. The clinical aspects include pathogenesis, symptomatology and diagnostic methods, and the fields of prophylaxis and therapy in all branches of medicine and surgery, pharmacology and drug research.
The endeavour of the Editors-in-Chief and publishers of
Clinical Hemorheology and Microcirculation is to bring together contributions from those working in various fields related to blood flow all over the world. The editors of
Clinical Hemorheology and Microcirculation are from those countries in Europe, Asia, Australia and America where appreciable work in clinical hemorheology and microcirculation is being carried out. Each editor takes responsibility to decide on the acceptance of a manuscript. He is required to have the manuscript appraised by two referees and may be one of them himself. The executive editorial office, to which the manuscripts have been submitted, is responsible for rapid handling of the reviewing process.
Clinical Hemorheology and Microcirculation accepts original papers, brief communications, mini-reports and letters to the Editors-in-Chief. Review articles, providing general views and new insights into related subjects, are regularly invited by the Editors-in-Chief. Proceedings of international and national conferences on clinical hemorheology (in original form or as abstracts) complete the range of editorial features.
The following professionals and institutions will benefit most from subscribing to
Clinical Hemorheology and Microcirculation: medical practitioners in all fields including hematology, cardiology, geriatrics, angiology, surgery, obstetrics and gynecology, ophthalmology, otology, and neurology. Pharmacologists, clinical laboratories, blood transfusion centres, manufacturing firms producing diagnostic instruments, and the pharmaceutical industry will also benefit.
Important new topics will increasingly claim more pages of
Clinical Hemorheology and Microcirculation: the role of hemorheological and microcirculatory disturbances for epidemiology and prognosis, in particular regarding cardiovascular disorders, as well as its significance in the field of geriatrics. Authors and readers are invited to contact the editors for specific information or to make suggestions.
Abstract: We studied erythrocyte aggregation parameters in 10 normal subjects and 10 diabetic patients. We measured erythrocyte aggregation on washed erythrocytes resuspended in their own or autologus plasma with 0.40 adjusted hematocrit both with glycosylated or control fibrinogen at different concentrations (from 0.5 g/l to 2.5 g/l). The cross match experiments emphasized the role of RBC suspension medium. No effect has been demonstrated on RBC aggregation with glycosylated fibrinogen.
Abstract: On evaluation of new haemorheological parameters strict criteria had to be applied. The normal range has to be determined by means of a sufficient number of suitable subjects. Sensibility, specificity and predictive value should be known. Internal and external quality controls must be performed in the daily laboratory routine. The design of clinical trials with rheological active substances should be double-blind and placebo-controlled. The method of matched pairs is especially appropriate to achieve homogeneity in placebo and verum groups.
Abstract: Serial measurement of blood rheology is an important part of the assessment of rheological therapy in clinical trials. A nomogram can be used to calculate the number of patients and matched controls required if a trial is to have the statistical power to show a significant difference in rheological tests. This calculation requires prior knowledge of the precision of the test and of the biological variability of the rheological measurement within the patient group.